Literature DB >> 2839834

Anti-L3T4 antibody inhibits the lysis of H-2 class II antigen-negative target cells by L3T4+ cytotoxic T lymphocytes.

S Macphail1, O Stutman.   

Abstract

Anti-L3T4 monoclonal antibodies inhibit the cytotoxic activity of L3T4+ cytotoxic T lymphocytes specific for H-2 class I antigens. The P815 target cells used to detect this population of murine cytolytic cells are shown by immunofluorescence, radioimmunoprecipitation, and RNA blot analysis not to express H-2 class II protein or mRNA. Contrary to previously proposed models regarding its function, we conclude that the L3T4 molecule is involved at some stage of the lytic interaction between the class I-specific L3T4+ effector cell and its target cell by a mechanism for which there is not an obligatory requirement for H-2 class II antigen expression by the target cell. L3T4 may be an early component of the system that transduces the activation signal from the T-cell receptor complex to the cytoplasm, a cell-surface receptor for a yet undefined natural ligand that delivers a negative signal to the killer T cell, or it may modulate the avidity of the antigen-specific T-cell receptor through a direct physical association with it.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839834      PMCID: PMC281717          DOI: 10.1073/pnas.85.14.5205

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Distinct roles for L3T4 in T cell activation.

Authors:  J L Greenstein; M V Sitkovsky; S J Burakoff
Journal:  Fed Proc       Date:  1987-02

2.  The T cell repertoire may be biased in favor of MHC recognition.

Authors:  M Blackman; J Yagüe; R Kubo; D Gay; C Coleclough; E Palmer; J Kappler; P Marrack
Journal:  Cell       Date:  1986-11-07       Impact factor: 41.582

3.  The major histocompatibility complex-restricted antigen receptor on T cells. IX. Role of accessory molecules in recognition of antigen plus isolated IA.

Authors:  D Gay; C Coeshott; W Golde; J Kappler; P Marrack
Journal:  J Immunol       Date:  1986-03-15       Impact factor: 5.422

4.  Role of the L3T4-antigen in T cell activation. II. Inhibition of T cell activation by monoclonal anti-L3T4 antibodies in the absence of accessory cells.

Authors:  P Wassmer; C Chan; L Lögdberg; E M Shevach
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

5.  Search for class II major histocompatibility complex molecular involvement in the response of Lyt-2+ cytotoxic T lymphocyte precursors to alloantigen.

Authors:  L Romani; M G Mage
Journal:  Eur J Immunol       Date:  1985-11       Impact factor: 5.532

6.  Activation requirements for normal T cells: accessory cell-dependent and -independent stimulation by anti-receptor antibodies.

Authors:  M Bekoff; R Kubo; H M Grey
Journal:  J Immunol       Date:  1986-09-01       Impact factor: 5.422

7.  T-cell recognition of a chimaeric class II/class I MHC molecule and the role of L3T4.

Authors:  H Golding; J McCluskey; T I Munitz; R N Germain; D H Margulies; A Singer
Journal:  Nature       Date:  1985 Oct 3-9       Impact factor: 49.962

8.  Perturbation of the T4 molecule transmits a negative signal to T cells.

Authors:  I Bank; L Chess
Journal:  J Exp Med       Date:  1985-10-01       Impact factor: 14.307

9.  Capacity of purified Lyt-2+ T cells to mount primary proliferative and cytotoxic responses to Ia- tumour cells.

Authors:  J Sprent; M Schaefer
Journal:  Nature       Date:  1986 Aug 7-13       Impact factor: 49.962

10.  Role of L3T4 in antigen-driven activation of a class I-specific T cell hybridoma.

Authors:  J L Greenstein; B Malissen; S J Burakoff
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

View more
  1 in total

1.  The role of "indirect" recognition in initiating rejection of skin grafts from major histocompatibility complex class II-deficient mice.

Authors:  H Auchincloss; R Lee; S Shea; J S Markowitz; M J Grusby; L H Glimcher
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.